

**Prospera**™ Transplant assessment



Prospera<sup>™</sup> precision – for critical decisions when the stakes are high

# Introducing Prospera

Prospera is powered by highly optimized, proprietary cell-free DNA (cfDNA) technology. As part of your tool kit, Prospera assesses all types of kidney transplant rejection<sup>2</sup> with the greatest precision.<sup>1,3</sup>

- Simpler and less invasive than biopsy
- More sensitive and specific than current assessment tools across all types of rejection<sup>2,4,5</sup>
- Up to 5x less variability than first-generation donor-derived cell-free DNA technology<sup>1,3</sup>

#### Powering clear and confident decisions

Developed by Natera with our trusted legacy in cfDNA, Prospera is optimized to be the most precise tool for early, clinically meaningful rejection assessment.<sup>1,3</sup>



# Experts in cell-free DNA. Optimized for transplant.

To improve the management of organ transplantation, cancer, and reproductive health, Natera is harnessing the power of cfDNA from a single blood sample and a methodology that uses single-nucleotide polymorphisms (SNPs) for noninvasive testing.

> Organ Transplantation Highest-performing dd-cfDNA test

**Oncology** First custom-built circulating-tumor DNA test

**Reproductive Health** Pioneered SNP-based technology to a broad prenatal-testing product suite

#### Refined workflow. Only from Natera.

Natera core technology and finely tuned workflows cut through the noise to deliver superior clinical and analytical performance.<sup>1,2</sup>

Proprietary Library Preparation Reduces background noise and variability in the cfDNA sample

**DNA Extraction** 

consistency in results

Efficiently extracts high-quality cfDNA

to remove impurities, reduce noise,

and produce significantly higher yield than traditional methods to increase

Target > 13,000 SNPs Curated informative and

larget > 13,000 SNPs Curated, informative, and pan-ethnic SNPs address population variability (including ethnicity and donor-recipient relatedness)



#### Proprietary Bioinformatics

Provide precise, highly accurate results based on our deep experience in cfDNA



~2M cfDNA tests performed

>100 clinicians, PhD's and scientists

90 countries worldwide



With all the rapid advances taking place in cfDNA at Natera, our unwavering commitment to improving the health and care of your patients remains constant.



<sup>‡</sup>Using a 1% dd-cfDNA threshold



# Patients first. Partners always.

EMR integration

## Pledging ongoing support and resources

#### Natera offers outstanding support for your patients

- Proactive billing outreach and price transparency

#### We also back you and other physicians with resources

- and receive patients' reports

#### Our initiatives specifically for your transplant nurses and coordinators

- patient care workflow

Natera welcomes all insurances. The goal of Natera's billing department is to make the process transparent and easy for our patients. In the rare event your patient has financial responsibility for Prospera, Natera offers flexible financial assistance programs and will work closely with your patient to ensure there is no hardship on them or their family.

In all cases, the Natera team is here to help you, your staff, and your patients with any billing or reimbursement questions and needs at 650.480.5007.

#### PATIENTS

Mobile phlebotomy Payment plans Price transparency

## PHYSICIANS Clinical support Provider portal

#### NURSES

Operational support Ease of integration Patient portal program

• Complimentary mobile phlebotomy services available: 650.480.5007

• Direct support from clinical staff to discuss your patients' results • Prospera Provider Portal plus EMR integration options so you can easily order, track

• Dedicated operations team to ensure ease of integration into your current

• Participation in our ProsperaLink Patient Program so your team can help patients stay updated on their blood draws, compliance plan, and results

## Prospera precision. Setting a new standard through research.

Best-in-class transplant care depends on best-in-class assessment. Prospera is the most advanced cfDNA solution for assessing transplant rejection-reinforced by ongoing research efforts:

#### Sigdel et al **Clinical Validation** Published 2019

- Conducted with the University of California, San Francisco
- Largest biopsy-matched study conducted in renal transplantation assessing the use of cell-free DNA
- The first to publish performance of cell-free DNA testing in subclinical, surveillance setting

#### **ProActive Registry** Study Now enrolling

- Largest clinical utility study evaluating cell-free DNA; includes more than 3,000 kidney transplant patients studied for three years
- Long-term assessment of high-risk recipients for up to 5 years post-transplantation
- Personalized transplant management protocols using cell-free DNA data

#### **Research with MMDx** (Molecular Microscope Diagnostic System) Now enrolling

- Global, prospective multicenter study under the leadership of Dr. Philip Halloran
- 300 patients to be comprehensively evaluated with clinical information, cell-free DNA measures, biopsies, molecular microscope, evaluations, and donor-specific antibodies (DSA)
- Integrated data analysis to better inform noninvasive and interventional management in kidney transplantation

#### REFERENCES

- 1 Altug Y, Liang N, Ram R, et al. Analytical validation of a single-nucleotide polymorphism-based donor-derived cell-free DNA assay for detecting rejection in kidney transplant patients [published online February 19, 2019]. Transplantation. 2019. doi: 10.1097/TP.00000000002665 2 Sigdel TK, Archila FA, Constantin T, et al. Optimizing detection of kidney transplant injury by assessment of donor-derived cell-free DNA via
- massively multiplex PCR. J Clin Med. 2018;8(1):pii E19
- 3 Grskovic M, Hiller DJ, Eubank LA, et al. Validation of a clinical-grade assay to measure donor-derived cell-free DNA in solid organ transplant recipients. J Mol Diagn. 2016;18(6):890-902
- 4 Bromberg JS, Brennan DC, Poglio E, et al. Biological variation of donor-derived cell-free DNA in renal transplant recipients: clinical implications. J Appl Lab Med. 2017;2(3):309-321
- 5 Bloom RD, Bromberg JS, Poggio ED, et al. Cell-free DNA and active rejection in kidney allografts. J Am Soc Nephrol. 2017;28(7):2221-2232. doi: 10.1681/ASN.2016091034.
- 6 Huang E, Sethi S, Peng A, et al. Early clinical experience using donor-derived cell-free DNA to detect rejection in kidney transplant recipients. Am J Transplant. 2019; 19:1663-1670.

#### 201 Industrial Road, Suite 410 | San Carlos, CA 94070 | www.natera.com | 1.650.249.9090 | Fax 1.650.730.2272

This test was developed by Natera, Inc., a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. © 2019 Natera, Inc. PRO\_PhysicianBrochure\_20190903\_NAT-801997



